Vertex Pharmaceuticals

VRTXintermediary

Vertex Pharmaceuticals dominates the cystic fibrosis market with Trikafta and is expanding into gene editing (Casgevy for sickle cell), non-opioid pain (suzetrigine), and kidney disease. Its CF franchise generates massive cash flow to fund pipeline diversification.

⇄ Compare

Produkte & Umsatz

Umsatzanteil nach Produkt

Umsatzaufschlüsselung ($11.2B)

Statische Daten (Echtzeitfinanzen werden geladen…)

Cystic Fibrosis (Trikafta) (78%)

Gene Therapy (Casgevy) (8%)

Other Products & Collaborations (14%)

Segmentzusammensetzung und Hauptkunden

Produktdetails

Trikafta / Kaftrio65%

Triple-combination CFTR modulator for cystic fibrosis — standard of care

Casgevy (exa-cel)8%

CRISPR-based gene therapy for sickle cell disease and beta-thalassemia

Pain Pipeline (VX-548, suzetrigine)10%

Non-opioid NaV1.8 pain inhibitor for acute and neuropathic pain

Lieferkettenbeziehungen

Wettbewerber

Eli Lilly and Company

Pain therapeutics pipeline

Auswirkung: Competing in non-opioid pain

Regeneron Pharmaceuticals

Gene editing and rare disease

Auswirkung: Competing in genetic medicine

Pfizer Inc.

Gene therapy and rare disease

Auswirkung: Limited overlap

Makro- und Marktkontext

제약 / 바이오Sektornachrichten

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

Nächste Katalysatoren

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

Aktuelle Nachrichten

Nachrichten laden...

KI-Analyse

Klicken Sie auf "KI-Analyse abrufen" für eine KI-gestützte Lieferkettenanalyse von Vertex Pharmaceuticals.

Unternehmensinformationen

Hauptsitz

Boston, Massachusetts, USA

Gegründet

1989

Mitarbeiter

10,400+

Website

vrtx.com

Sektorübersicht — 제약 / 바이오

Sektornachrichten